Eicke bib

from Wikipedia, the free encyclopedia

Eicke Latz (born July 11, 1970 in Wiesbaden ) is a German physician ( immunology ). He is professor and director of the Institute for Innate Immunity at the University of Bonn, which was founded in 2010 .

Life

Latz studied medicine at the Georg August University of Göttingen and the Free University of Berlin and received his doctorate in 2001 from the Humboldt University of Berlin . As a post-doctoral student , he was at the University of Massachusetts Medical School in Worcester, Massachusetts , where he became Assistant Research Professor in 2003 and Assistant Professor in 2006. In 2007 he founded the NanoMedicine Institute of the University of Massachusetts there and was its co-director. At the same time he became a professor in Bonn in 2009 and founded the Institute for Innate Immunity there. The institute works with the University of Massachusetts and the Norwegian Technical University in Trondheim. He is also a professor at UMass in Worcester.

He is one of the founders of the International Innate Immunity Consortium (IIIC).

plant

He is concerned with the receptors for pathogens and inflammatory reactions of the innate immune system , a research field that was given a great boost by the discovery of TLRs in the 1990s by Bruce Beutler (Nobel Prize 2011) and Shizuo Akira . For example, he discovered that the inflammasome NLRP3 is active in the brain of patients with Alzheimer's disease and that the beta-amyloid aggregates in Alzheimer's disease lead to inflammatory reactions and cognitive degeneration in the mouse model. Latz also found that these NLRP3 inflammasomes recognize damage to lysosomes . In 2010 he discovered the role of cholesterol crystals in inflammation in the development of arteriosclerosis and in 2009 he was one of the discoverers of the AIM-2 receptor, which reacts to double-stranded virus DNA in the cytoplasm of body cells. He was involved in the identification of the activation mechanism of TLR 9 (2007) and its localization in endosomes in the cell with its origin in the endoplasmic reticulum .

In 2013 he used other mechanisms to clarify how HDL, commonly known as good cholesterol , affects the immune system to prevent inflammatory reactions that are important for the development of arteriosclerosis. This positive role of HDL had been known for a long time, but it was also known that high HDL proportions alone are not sufficient for the explanation. According to the findings of Latz and colleagues, HDL particularly activates the transcription regulator ATF 3, which downregulates an excessive immune response.

He worked with Veit Hornung (Institute for Clinical Chemistry and Pharmacology at the University of Bonn).

In 2015, Eicke Latz co-founded IFM Therapeutics LLC in Boston . In June 2016, IFM Therapeutics received $ 27 million in Series A funding . The company was acquired by Bristol-Myers Squibb for $ 300 million in August 2017 . Including the possible milestone payments for two development products, the sale can reach a volume of 2.3 billion US dollars.

Honors

In 2011 he received the GlaxoSmithKline Clinical Science Award (for research into the development of arteriosclerosis), in 2009 the Dana Foundation Award and in 2004 the Prize of the Federation of Clinical Immunology Societies. On May 25, 2016, Eicke Latz was elected a member ( matriculation number 7690 ) of the Leopoldina . For 2018 Latz was awarded a Gottfried Wilhelm Leibniz Prize .

Fonts (selection)

  • with T. Sam Xiao, Andrea Stutz: Activation and regulation of the inflammasomes . In: Nature Reviews Immunology , Volume 13, 2013, 397-411
  • with Heneka, Stutz, DT Golenbock u. a .: NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP / PS1 mice . In: Nature , Volume 493, 2013, pp. 674-678, PMID 23254930
  • with Halle, Hornung, Petzold, Stewart, Monks, Reinheckel, Fitzgerald, Moore, Golenbock: The NALP3 inflammasome is involved in the innate immune response to amyloid-beta . In: Nature Immunology , Volume 8, 2008, pp. 857-865.
  • with P. Duewell, Fitzgerald, Hornung a. a .: NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals . In: Nature , Volume 464, 2010, pp. 1357-1361, PMID 20428172 .
  • The inflammasomes: mechanisms of activation and function . In: Current Opinion in Immunology , Volume 22, February 2010, 28-33.
  • with A. Ablasser , M. Charrel-Dennis, F., Bauernfeind, V. Hornung, G. Horvath, DR Caffrey, KA Fitzgerald: AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC . In: Nature , Volume 458, 2009, pp. 514-518.
  • mit Ablasser, Bauernfeind, Hartmann, Hornung, Fitzgerald: RIG-I-dependent sensing of poly (dA: dT) through the induction of an RNA polymerase III-transcribed RNA intermediate . In: Nature Immunology , Volume 10, 2009, pp. 1065-72.
  • with V. Hornung: Intracellular DNA recognition . In: Nature Review Immunology , Volume 10, 2010, pp. 123-130.
  • with Rathinam, Hornung, Fitzgerald a. a .: The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses . In: Nature Immunology , Volume 11, 2010, pp. 395-402.
  • with Hornung, Bauernfeind, Halle, Samstad, Kono, Rock, Fitzgerald: Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization . In: Nature Immunology , Volume 9, 2008, pp. 847-856.
  • with Visintin, Espevik, Golenbock u. a .: Ligand-induced conformational changes allosterically activate Toll-like receptor 9 . In: Nature Immunology , Volume 8, 2007, pp. 772-779
  • with Schoenemeyer, Visintin, Fitzgerald, Monks, Kneter, Lien, Nilsn, Espevik, Golenbock: TLR9 signals after translocating from the ER to CpG DNA in the lysosome . In: Nature Immunology , Vol. 5, 2004, pp. 190-198.
  • with A. Visintin, T. Espevik, DT Golenbock: Mechanisms of TLR9 activation . In: J Endotoxin Res. , Vol. 10, 2004, pp. 406-412.

literature

  • Leopoldina Newly elected members 2016, Leopoldina, Halle (Saale) 2017, p. 24 ( PDF )

Web links

Individual evidence

  1. ↑ Julia Koch: Defensive auxiliary force . In: Der Spiegel . No. 49 , 2009 ( online ).
  2. ↑ Press release University of Bonn 2013
  3. ↑ Dominic de Nardo, Larisa Labzin, Latz a. a., High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3 . In: Nature Immunology , Volume 15, 2014, pp. 152-160
  4. ↑ New biotech at the University of Bonn. In: uni-bonn.de. June 8, 2017, accessed March 12, 2018 .
  5. ↑ IFM Therapeutics Raises $ 27 Million Series A Financing Led by Atlas Venture and Abingworth. In: businesswire.com. June 22, 2016, accessed March 12, 2018 .
  6. ↑ Innately Innovative: IFM Therapeutics Acquired By BMS. In: lifescivc.com. August 3, 2017, accessed March 12, 2018 .
  7. ↑ Member entry by Prof. Dr. Eicke Latz at the German Academy of Sciences Leopoldina , accessed on July 29, 2016.
personal data
SURNAME Latz, Eicke
BRIEF DESCRIPTION German immunologist
DATE OF BIRTH July 11, 1970
PLACE OF BIRTH Wiesbaden